Visual field measurements using Heru Visual Field Multi-platform application downloaded on two different commercially available augmented reality devices

Abstract

Purpose : 1- To evaluate the comparability of visual field measurements between Heru visual field application (Heru, Miami, FL) as a multiplatform visual field-testing application downloaded on two different commercially available augmented reality devices and the standard automated perimetry in both normal patients and those with visual field defects. 2- Evaluate the reproducibility of Heru VF measurements in normal and pathologic patients.

Methods : This prospective comparative clinical study included 81 eyes, 40 normal eyes and 41 eyes of patients with glaucoma and neuro-ophthalmic diseases (hemianopic, altitudinal and ring scotomas). VF results were obtained using Heru VF software downloaded on Magic Leap 1 (Magic Leap, Plantation, FL; 41 eyes) headset, on Hololens 2 (Microsoft Inc, Redmond, WA; 40 eyes) and Humphrey Field Analyzer (HFA) 800 series perimeter (Carl Zeiss Meditec, Inc, Dublin, CA, USA; 81 eyes). All patients underwent 24-2 test pattern with all 3 testing devices. Correlations of threshold values and mean deviations (MD) obtained using Heru VF and HFA were calculated to determine agreements between them. To evaluate the reproducibility of Heru VF, 39 eyes (27 normal and 12 pathological eyes) were tested twice on the same day with 5-minutes in between, and the intraclass correlation coefficient was calculated.

Results : Mean deviation (MD) and Threshold values obtained using Heru VF software application downloaded on the two different platforms showed strong correlations with those of Humphrey Field Analyzer (HFA) (R=0.91 and R=0.8, P <0.001, respectively). The Heru VF software was reproducible with ICC of 0.974 (95%CI 0.94-0.987) for MD and 0.8 (95%CI 0.813-0.845) for threshold values in normal eyes and in patients with glaucoma and neuro-ophthalmic diseases.

Conclusions : Central visual field measurements obtained using Heru VF as a multi-platform application downloaded on two different commercially available augmented reality devices were comparable to HFA in normal, glaucoma, and neuro-ophthalmology patients. Heru VF measurements are reproducible in normal and pathologic patients.

This is a 2021 ARVO Annual Meeting abstract.